Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrolizumab Immunotherapy in Patients With Advanced or Metastatic Refractory Lung Cancer

NCT06538012 is registered in ClinicalTrials.gov with Essen Biotech as lead sponsor.

NCT NCT06538012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06538012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrolizumab Immunotherapy in Patients With Advanced or Metastatic Refractory Lung Cancer
Lead sponsor
Essen Biotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 20, 2024
Completion date
December 28, 2026
Enrollment
85 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, lung cancer metastatic, lung cancer recurrent, lung cancer, non-small cell